Literature DB >> 2265462

DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II).

L Pendyala1, A V Arakali, P Sansone, J W Cowens, P J Creaven.   

Abstract

The quadrivalent second-generation platinum complex iproplatin and an in vivo divalent metabolite of iproplatin, cis-dichloro-bis-isopropylamine platinum (CIP) were tested for binding to DNA in vitro. DNA binding was determined according to radioactivity measured using [14C]-iproplatin and [14C]-CIP and also by platinum content. Results indicate that (a) iproplatin shows negligible binding to DNA, (b) CIP binds to DNA in a time-dependent fashion, and (c) the isopropylamine ligand is intact when CIP is bound to DNA. Glutathione (GSH) inhibits the binding of CIP to DNA, possibly by inhibiting binding to DNA of the aquated form of CIP.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2265462     DOI： 10.1007/bf00685722

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  11 in total

Review 1.  Platinum antitumour agents.

Authors:  J C Dabrowiak; W T Bradner
Journal:  Prog Med Chem       Date:  1987

2.  Cellular resistance to platinating agents in ovarian carcinoma.

Authors:  P A Andrews; M P Murphy; S B Howell
Journal:  Prog Clin Biol Res       Date:  1986

3.  Glutathione-mediated activation of anticancer platinum(IV) complexes.

Authors:  A Eastman
Journal:  Biochem Pharmacol       Date:  1987-12-01       Impact factor: 5.858

4.  The effects of platinum ethylenediamine dichloride on the template activity of DNA.

Authors:  T Giraldi; D M Taylor
Journal:  Biochem Pharmacol       Date:  1974-05-01       Impact factor: 5.858

Review 5.  Antitumor activity of platinum complexes.

Authors:  J Drobník
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Uptake and metabolism of iproplatin in murine L1210 cells.

Authors:  L Pendyala; J R Walsh; M M Huq; A V Arakali; J W Cowens; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Studies on the human metabolism of iproplatin.

Authors:  L Pendyala; B S Krishnan; J R Walsh; A V Arakali; J W Cowens; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans.

Authors:  L Pendyala; J W Cowens; G B Chheda; S P Dutta; P J Creaven
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

9.  Interaction of the antitumor agents cis,cis,trans-PtIV(NH3)2Cl2(OH)2 and cis,cis,trans-PtIV[(CH3)2CHNH2]2Cl2(OH)2 and their reduction products with PM2 DNA.

Authors:  E E Blatter; J F Vollano; B S Krishnan; J C Dabrowiak
Journal:  Biochemistry       Date:  1984-10-09       Impact factor: 3.162

10.  Activity of JM9 in advanced ovarian cancer: a phase I-II trial.

Authors:  V H Bramwell; D Crowther; S O'Malley; R Swindell; R Johnson; E H Cooper; N Thatcher; A Howell
Journal:  Cancer Treat Rep       Date:  1985-04
View more
  11 in total

1.  Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.

Authors:  L R Kelland; M Jones; G Abel; M Valenti; J Gwynne; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Kinetics and mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione.

Authors:  K Lemma; J Berglund; N Farrell; L I Elding
Journal:  J Biol Inorg Chem       Date:  2000-06       Impact factor: 3.358

Review 3.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

4.  The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.

Authors:  M G Ormerod; R M Orr; C F O'Neill; T Chwalinski; J C Titley; L R Kelland; K R Harrap
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

5.  Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin.

Authors:  Z H Siddik; G Thai; M Yoshida; Y P Zhang; A R Khokhar
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors.

Authors:  M Yoshida; A R Khokhar; Y P Zhang; G Thai; Z H Siddik
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes.

Authors:  V Boudný; O Vrána; F Gaucheron; V Kleinwachter; M Leng; V Brabec
Journal:  Nucleic Acids Res       Date:  1992-01-25       Impact factor: 16.971

8.  Intracellular glutathione and cytotoxicity of platinum complexes.

Authors:  L Pendyala; P J Creaven; R Perez; J R Zdanowicz; D Raghavan
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.

Authors:  R M Orr; C F O'Neill; M C Nicolson; C F Barnard; B A Murrer; C M Giandomenico; J F Vollano; K R Harrap
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

10.  Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells.

Authors:  Ulrike Olszewski; Ernst Ulsperger; Klaus Geissler; Gerhard Hamilton
Journal:  J Exp Pharmacol       Date:  2011-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.